Humanigen, Inc. has the chance to meet a key area of medical need in the treatment of COVID-19 with new Phase III data in a population at high risk of progressing to mechanical ventilation or death, where other companies have often met failure.
The Burlingame, CA-based company reported on 29 March positive topline results from its Phase III study of the granulocyte macrophage colony-stimulating factor (GM-CSF)-targeting antibody lenzilumab in patients hospitalized with COVID-19....